aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Anna Heim
May 27, 2024
If 11 figures is your attention threshold, you may be interested in learning that the combined enterprise value (EV) of Spanish startups surpassed €100 billion in 2023, according to Dealroom’s latest report on the Spanish tech ecosystem. As we’ll see, venture investment into Spanish startups also held up quite well, with €2.2BN raised across some 850 funding rounds.
Spain’s venture capital tally was lower last year than in 2021 and 2022; that’s no surprise as these years were outliers. Unlike other places, though, the country hasn’t fallen below pre-pandemic levels of activity. In 2019, for reference, Spanish startups had collectively raised €1.9BN in venture capital.
But first, there are several ways to look at Spain’s 11-figure startup EV. On the one hand, it puts Spain ahead of Norway, Italy or Portugal. On the other hand, with a combined value of $191BN, Cambridge’s tech ecosystem alone is almost worth double Spain’s. (With $1 worth €0.92 today, please forgive us for skipping conversions.)
A lot could be said on whether Spain is doing enough to support entrepreneurship — but for today, let’s stick to facts and numbers.
Adding time as a factor, France reached €100BN in combined startup EV six years ago, and Germany nine years ago. But the value of Spanish tech is also one of the fastest growing in Europe, Dealroom noted in a slide. Give them more time, and maybe some Spanish startups will become decacorns and more, too.
Here’s the funnel according to the report:
With a total of €2.2BN in venture investment, 2023 results moved the needle in the right direction, but mostly for the top of the funnel. Investment volume for “Early-stage” — pre-seed, seed and Series A — was at an all-time high last year, and the Series B and Series C stages remained strong. However, late stage activity was “quiet,” per Dealroom, with only two mega-rounds (into veteran data management platform Denodo, which has long since relocated to the US; and the data-driven events startup Fever.)
The slowdown in late stage activity isn’t unique to Spain but, like elsewhere, it could be a concern. Startup activity isn’t only a funnel: It is also supposed to be a circle.
For instance, high-profile scaleups often turn into founder factories; in Spain, it’s been the case with Fever, but also Cabify, job&talent, Glovo and wallbox. But without liquidity events, it becomes more difficult for former employees to become angels or start new companies.
That’s also a necessity on the VC side, with exits providing liquidity that can be reinjected into early stage deals. Without large M&As and IPOs, there’s always a risk funds will be deprived of capital to invest anew.
Spanish VCs don’t seem worried, though; time will do its thing, they suggest. Jaime Novoa, a partner at Kfund, commented in the report that he and his colleagues are “very confident that several companies being funded now will become scaleups in the next five to ten years.” He cited as a positive signal how early stage activity “remains very healthy.”
Not only is the early stage quite active, but the teams getting funded are also in line with what Europe may want to see more of. Most of 2023’s VC funding into Spanish startups went to climate tech, followed by biotech and clean energy. It is too early to tell how many of these could become centaurs, but it will definitely be worth tracking.
Share:
PharmEasy’s $5.6 billion value shrinks to $456 million, investor data shows
Indian online pharmacy PharmEasy’s valuation now stands at about $456 million, according to disclosures from its investor Janus Henderson, a 92% drop from its peak valuation of $5.6 billion. The British American global asset firm’s Global Research Fund values its holding of 12.9 million shares in PharmEasy at $766,043, according to its latest filing for the period ending September. The fund had originally spent $9.4 million to acquire these shares. The persistent low valuation comes despite Pha
Dec 26, 2024
PharmEasy investor cuts value of its stake drastically, implying new valuation of $456M
Indian online pharmacy PharmEasy is now being valued at about $456 million after its investor Janus Henderson said in a filing that it valued its stake of 12.9 million shares in the startup at $766,043. The asset manager’s Global Research Fund had originally spent $9.4 million to acquire these shares. This valuation is 92% less than PharmEasy’s all-time-high price tag of $5.6 billion. The persistent low valuation comes despite PharmEasy securing more than $200 million in fresh capital earlier
Dec 26, 2024
Elon Musk’s xAI lands $6B in new cash to fuel AI ambitions
Updated December 25, 12:21 p.m. Pacific: Added details of xAI’s valuation and Kingdom Holdings’ contribution. xAI, Elon Musk’s AI company, has raised $6 billion in a Series C financing round. The company announced this week that Andreessen Horowitz , Blackrock, Fidelity, Lightspeed, MGX, Morgan Stanley, OIA, QIA, Sequoia Capital, Valor Equity Partners, Vy Capital, Nvidia, AMD, and others participated. Kingdom Holdings, the Saudi conglomerate holding company, invested roughly $400 million in the
Dec 25, 2024
Don't miss our latest news and updates. Subscribe to the newsletter